Проблемы эндокринотерапии рака молочной железы у мужчин

1. Макаренко Н.П. Рак молочной железы у мужчин. Диссертация на соискание ученой степени кандидита медицинских наук. М., 1972.
2. Островская И.М., Островцев Л.Д, Ефимова О.Ю. Рак молочной железы у мужчин. М.: Медицина, 1988.
3. Macdonald G, Paltiel C, Olivotto IA, Tyldesley S. A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer. Ann Onc 2005; 16: 1442–8.
4. El-Tamer MB, Komenaka IA, Troxel A et al. Men with breast cancer have better disease-specific survival than women. Arch Surg 2004; 139: 1079–82.
5. Giordano SH, Cohen DS, Buzdar AU et al. Breast carcinoma in men: a population-based study. Cancer 2004; 101 (1): 51–7.
6. Летягин В.П. Опухоли молочных желез у мужчин. Маммология. 2006; 2.
7. Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother 2007; 8 (2): 193–202.
8. Первичные опухоли молочной железы. Практическое руководство по лечению. Под редакцией проф. В.П.Летягина М., 2005.
9. Летягин В.П., Высоцкая И.В., Легков А.А. и др. Лечение доброкачественных и злокачественных заболеваний молочной железы. М., 1997.
10. Nahleh ZA, Srikantiah R, Safa M et al. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 2007; 109: 1471–7.
11. Fentiman IS, Fourquet A, Hortobagyi G. Male breast cancer. Lancet 2006; 367: 595–604.
Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother 2007; 8 (2).
12. Weiderpass E, Ye W, Adami HO et al. Breast cancer risk in male alcoholics in Sweden. Cancer Causes Control 2001; 12 (7): 661–4.
13. Rudlowski C, Friedrichs N, Faridi A et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004; 84: 215–23.
14. Wang-Rodriguez J, Cross K, Gallagher S et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002; 15: 853–61.
15. Rayson D, Erlichman C, Suman VJ et al. Molecular markers in male breast carcinoma. Cancer 1998; 83: 1947–55.
16. Tanner M, Isola J, Wiklund T et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracyclinebased adjuvant chemotherapy in Her-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 2428–36.
17. Treves N. The treatment of cancer, especially inoperable cancer, of the male breast by ablative surgery (orchiectomy, adrenalectomy, and hypophysectomy) and hormone therapy (estrogens and corticosteroids); an analysis of 42 patients. Cancer 1959; 12: 820–32.
18. Vorobiof DA, Falkson G. Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer. Cancer 1987; 59: 688–9.
19. Lopez M. Cyproterone acetate in the treatment of metastatic cancer of the male breast. Cancer 1985; 55: 2334–6.
20. Mitsuyasu R, Bonomi P, Anderson K et al. Response to megestrol in male breast carcinoma. Arch Intern Med 1981; 141: 809–10.
21. Patel JK, Nemoto T, Dao TL. Metastatic breast cancer in males. Assessment of endocrine therapy. Cancer 1984; 53: 1344–6.
22. Kantarjian H, Yap HY, Hortobagyi G et al. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 1983; 143: 237–40.
23. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992; 65: 252–4.
24. Patel HZ, 2nd, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer 1989; 64: 1583–5.
25. Kantarjian H, Yap HY, Hortobagyi G et al. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 1983; 143: 237–40.
26. Jaiyesimi IA, Buzdar AU, Sahin AA et al. Carcinoma of the male breast. Ann Intern Med 1992; 117: 771–7.
27. Goss PE, Reid C, Pintilie M et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer 1999; 85: 629–39.
28. Ribeiro G. Male breast carcinoma – a review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer 1985; 51: 115–1192.
29. Anelli TF, Anelli A, Tran KN et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994; 74: 74–7.
30. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of Letrozole versus Tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women; analyses of survival and update of efficacy from the international Letrozole breast cancer group. J Clin Oncol 2003; 21: 2101–9.
31. Paepke S, Tulusan A, Kiesel L et al. A multi-center study of pre-operative treatment with Letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer. Proc ASCO 2003; 22: abst. 321.
32. Dimitrov NV, Colucci P, Nagpal S. Some Aspects of the Endocrine Profile and Management of Hormone-Dependent Male Breast Cancer. The Oncologist 2007; 12: 798–807.
33. Nahleh ZA. Hormonal therapy for male breast cancer: A different approach for a different disease. Cancer Treat Rev 2006; 32: 101–5.
34. Mauras N, O'Brien KO, Klein KO et al. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000; 85: 2370–7.
35. Giordano SH, Hortobagyi G. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 2006; 24: e42–3.
36. Lopez M, DiLauro L, Lazzaro B et al. Hormonal treatment of disseminated male breast cancer. Oncology 1985; 42: 345–9.
37. Harris AL, Dowsett M, Stuart-Harris R et al. Role of aminoglutethimide in male breast cancer. Br J Cancer 1986; 54: 657–60.
38. Patterson JS, Battersby LA, Bach Bk. Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep 1980; 64: 801–4.
39. Wong NS, Ooi WS, Pritchard KI. Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer. J Clin Oncol 2007; 25 (24): 3787.
40. Rossmann ED, Liljegren A, Bergh J. Male breast cancer – how to treat? Breast Cancer Online 2007; 10 (8): 1–6, Cambridge University Press.
41. Giordano SH, Valero V, Buzdar AU et al. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002; 25: 235–7.
42. Arriola E, Hui E, Dowsett M, Smith IE. Aromatase inhibitors and male breast cancer. Clin Transl Oncol 2007; 9: 192–4.
43. Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer. J Surg Oncol 2005; 90: 26–30.
44. Italiano A, Largillier R, Marcy PY et al. Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Interne 2004; 25: 323–4. French.
45. Arriola E, Hui E, Dowsett M, Smith IE. Aromatase inhibitors and male breast cancer. Clin Transl Oncol 2007; 9: 192–4.

Е.И.Борисова, И.Ю.Воронина, С.Л.Гуторов

ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН